These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 1415199)
1. The uremic dyslipidemia: a cross-sectional and longitudinal study. Avram MM; Goldwasser P; Burrell DE; Antignani A; Fein PA; Mittman N Am J Kidney Dis; 1992 Oct; 20(4):324-35. PubMed ID: 1415199 [TBL] [Abstract][Full Text] [Related]
2. Longitudinal survey of apolipoproteins and atherogenic risk in hemodialysis and continuous ambulatory peritoneal dialysis patients. Burrell D; Antignani A; Fein PA; Goldwasser P; Mittman N; Avram MM ASAIO Trans; 1990; 36(3):M331-5. PubMed ID: 2123635 [TBL] [Abstract][Full Text] [Related]
3. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis. Siamopoulos KC; Elisaf MS; Bairaktari HT; Pappas MB; Sferopoulos GD; Nikolakakis NG Perit Dial Int; 1995; 15(8):342-7. PubMed ID: 8785232 [TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020 [TBL] [Abstract][Full Text] [Related]
5. The impact of CAPD treatment on lipid metabolism and cardiovascular risk. Tan D; Fein PA; Antignani A; Mittman N; Avram MM Adv Perit Dial; 1990; 6():233-7. PubMed ID: 1982815 [TBL] [Abstract][Full Text] [Related]
6. Fall of cholesterol with time on dialysis: impact on atherogenicity. Lapuz M; Avram MM; Lustig A; Goldwasser P; Antignani A; Fein PA; Mittman N ASAIO Trans; 1989; 35(3):258-60. PubMed ID: 2597459 [TBL] [Abstract][Full Text] [Related]
7. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins. Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239 [TBL] [Abstract][Full Text] [Related]
8. Lipid abnormalities in black renal patients. Burrell DE; Antignani A; Goldwasser P; Mittman N; Fein PA; Slater PA; Gan A; Avram MM N Y State J Med; 1991 May; 91(5):192-6. PubMed ID: 1857570 [TBL] [Abstract][Full Text] [Related]
9. Lipids, lipoproteins and apolipoproteins abnormalities in patients undergoing dialysis. Yang X; Wang H; Zhu Z; Deng A J Tongji Med Univ; 1997; 17(2):126-8. PubMed ID: 9639806 [TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease. Kim SB; Yang WS; Kang ES; Min WK; Park JS Perit Dial Int; 1997; 17(3):236-42. PubMed ID: 9237283 [TBL] [Abstract][Full Text] [Related]
11. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Tomura S; Nakamura Y; Doi M; Ando R; Ida T; Chida Y; Ootsuka S; Shinoda T; Yanagi H; Tsuchiya S; Marumo F Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250 [TBL] [Abstract][Full Text] [Related]
13. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Heimbürger O; Stenvinkel P; Berglund L; Tranoeus A; Lindholm B Nephron; 1996; 72(2):135-44. PubMed ID: 8684516 [TBL] [Abstract][Full Text] [Related]
14. Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis. Steele J; Billington T; Janus E; Moran J Atherosclerosis; 1989 Sep; 79(1):47-50. PubMed ID: 2803346 [TBL] [Abstract][Full Text] [Related]
15. Concentration of Lp(a) and other apolipoproteins in predialysis, hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients. Kimak E; Solski J; Janicka L; Ksaziek A; Janicki K Clin Chem Lab Med; 2000 May; 38(5):421-5. PubMed ID: 10952225 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Saltissi D; Morgan C; Rigby RJ; Westhuyzen J Am J Kidney Dis; 2002 Feb; 39(2):283-90. PubMed ID: 11840368 [TBL] [Abstract][Full Text] [Related]
18. Increased lipoprotein (a) and its relationships with other parameters of lipoprotein metabolism in chronic renal failure treated by hemodialysis. Yiğitoğlu MR; Polat MF; Akçay F; Ari Z; Uyanik BS; Ozilgili HM Jpn Heart J; 1997 Jan; 38(1):83-9. PubMed ID: 9186284 [TBL] [Abstract][Full Text] [Related]
19. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Navarro JF; Mora C; Muros M; García-Idoate G Nephron Clin Pract; 2003; 95(4):c128-35. PubMed ID: 14694274 [TBL] [Abstract][Full Text] [Related]
20. Variability of peritoneal clearances for apolipoprotein and its relationship to susceptibility for atherosclerotic changes in CAPD. Fein PA; Fletcher D; Antignani A; Goldwasser P; Jorden A; Lustig A; Avram MM Adv Perit Dial; 1989; 5():185-90. PubMed ID: 2577408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]